A 24-Week, Flexible-Dose, Open-label Extension Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder [EXTENSION OF 700056980]
Latest Information Update: 11 Aug 2023
Price :
$35 *
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- Acronyms Switch-Ext
- Sponsors Sumitomo Pharma America
- 16 May 2017 According to a Sunovion Pharmaceuticals media release, data will be presented as poster at the 170th Annual Meeting of the American Psychiatric Association (APA) 2017.
- 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
- 09 Jul 2013 New trial record